Search Within

Lisa Bodei

  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10)
  2. Meeting Abstract (9)
  3. Review (5)
  4. Editorial (2)
  5. Book Section (1)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (29)
  2. Molecular Imaging and Therapy Service (29)
  3. Radiology, Department of (29)
  4. Sloan Kettering Institute Postdocs (29)
  5. Solid Tumor Oncology Division (29)
  6. Center for Pancreatic Cancer Research (22)

More Groups

People
  1. Diane Reidy (17)
  2. Heiko Schoder (9)
  3. Michael Morris (9)
  4. Nitya Raj (9)
  5. Joseph O'Donoghue (8)
  6. Simone Krebs (8)

More People

Years
  1. 2024 (4)
  2. 2023 (7)
  3. 2022 (4)
  4. 2021 (4)
  5. 2020 (3)
  6. 2019 (3)

More Years

Publications
  1. Journal of Nuclear Medicine (8)
  2. European Journal of Nuclear Medicine and Molecular Imaging (4)
  3. Pancreas (3)
  4. Journal of Clinical Oncology (2)
  5. Clinical Cancer Research (1)
  6. Clinical Nuclear Medicine (1)

More Publications

Publishers
  1. Society of Nuclear Medicine (8)
  2. Springer (5)
  3. Lippincott Williams & Wilkins (4)
  4. American Society of Clinical Oncology (2)
  5. Elsevier Inc. (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (29)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • FRONTIER: FAPi Radioligand OpeN-label, phase 1 study to evaluate safety, Tolerability and dosImetry of [Lu-177]-PNT6555; a dose Escalation study for tReatment of patients with select solid tumors
    Meeting Abstract

    Juneau, D.; Kavan, P.; Metser, U.; Abikhzer, G.; Bodei, L.; Liberman, M.; Taunk, N.; O'Reilly, E. M.; Ma, J. S.; Cioci, R.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: A phase 1/2, first-in-human trial
    Journal Article

    Tendler, S.; Dunphy, M. P.; Agee, M.; O'Donoghue, J.; Aly, R. G.; Choudhury, N. J.; Kesner, A.; Kirov, A.; Mauguen, A.; Baine, M. K.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Sequencing of somatostatin-receptor–based therapies in neuroendocrine tumor patients
    Review

    Strosberg, J. R.; Al-Toubah, T.; El-Haddad, G.; Lagunes, D. R.; Bodei, L.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: Overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs
    Editorial

    Bodei, L.; Tuttle, R. M.; Grewal, R. K.; Mauguen, A.; Augensen, F.; Abusamra, M.; Mahajan, S.; Jayaprakasam, V. S.; Osborne, J. R.; Haque, S.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2024)

    Fulltext@MSK | Save
  • Case study #8: Alpha-therapy with radium-223 dichloride for metastatic castration-resistant prostate cancer
    Book Section

    Pasquini, L.; Morris, M. J.; Bodei, L.
    In Bodei, L.; Lewis, J. S.; Zeglis, B. M. (Eds.) Radiopharmaceutical Therapy (2023)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose-ascending study to evaluate the safety and tolerability of the therapeutic radiopharmaceutical (131)I-MIP-1095 for the treatment of metastatic castration-resistant prostate cancer
    Journal Article

    Laccetti, A. L.; Bodei, L.; O'Donoghue, J. A.; Weber, W. A.; Morris, M. J.
    Clinical Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • A pilot study of stereotactic body radiotherapy and (177)Lu-PSMA-617 for oligometastatic hormone sensitive prostate cancer
    Meeting Abstract

    Imber, B. S.; Bodei, L.; Humm, J.; Ionescu, A.; Wu, W.; Grkovski, M.; O'Donoghue, J.; Reddy, R. P.; Rimner, A.; Shasha, D.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting
    Editorial

    Singh, S.; Hope, T. A.; Bergsland, E. B.; Bodei, L.; Bushnell, D. L.; Chan, J. A.; Chasen, B. R.; Chauhan, A.; Das, S.; Dasari, A.; more...
    JNCI: Journal of the National Cancer Institute (2023)

    Fulltext@MSK | Save
  • SNMMI consensus statement on patient selection and appropriate use of (177)Lu-PSMA-617 radionuclide therapy
    Guidelines

    Hope, T. A.; Antonarakis, E. S.; Bodei, L.; Calais, J.; Iravani, A.; Jacene, H.; Koo, P. J.; Morgans, A. K.; Osborne, J. R.; Tagawa, S. T.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors
    Meeting Abstract

    Bodei, L.; Kavan, P.; Liberman, M.; Taunk, N.; Metser, U.; Juneau, D.; O'Reilly, E. M.; Ma, J.; Cioci, R.; Abdul Razak, A. R.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save